Items where authors include "Eichenfield, L.F."

Article

Paller, A.S., Ramien, M. orcid.org/0000-0001-9191-3611, Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (9 more authors) (2024) Low infection rates with long‐term dupilumab treatment in patients aged 6 months to 5 years: an open‐label extension study. Pediatric Dermatology. ISSN 0736-8046

Gooderham, M.J., de Bruin-Weller, M., Weidinger, S. et al. (7 more authors) (2024) Practical management of the JAK1 inhibitor abrocitinib for atopic dermatitis in clinical practice: special safety considerations. Dermatology and Therapy, 14 (8). 2285-2296,. ISSN 2193-8210

Paller, A.S., Siegfried, E.C., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (7 more authors) (2024) Infections in children aged 6 months to 5 years treated with dupilumab in a placebo-controlled clinical trial of moderate-to-severe atopic dermatitis. Pediatric Drugs, 26 (2). pp. 163-173. ISSN 1174-5878

Flohr, C., Cork, M.J. orcid.org/0000-0003-4428-2428, Ardern-Jones, M.R. et al. (6 more authors) (2023) Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. Journal of Dermatological Treatment, 34 (1). 2200866. ISSN 0954-6634

Cork, M.J., Thaçi, D., Eichenfield, L.F. et al. (8 more authors) (2023) Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis. Dermatology and Therapy, 13. pp. 2697-2719. ISSN 2193-8210

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (12 more authors) (2021) Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology, 184 (5). pp. 857-870. ISSN 0007-0963

Carr, A.N., DeWitt, T., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (15 more authors) (2020) Diaper dermatitis prevalence and severity : global perspective on the impact of caregiver behavior. Pediatric Dermatology, 37 (1). pp. 130-136. ISSN 0736-8046

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (19 more authors) (2020) Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology, 182 (1). pp. 85-96. ISSN 0007-0963

Thyssen, J.P., de Bruin-Weller, M.S., Paller, A.S. et al. (14 more authors) (2019) Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 33 (7). pp. 1224-1231. ISSN 0926-9959

Simpson, E.L., Bruin-Weller, M., Flohr, C. et al. (26 more authors) (2017) When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of The American Academy of Dermatology, 77 (4). pp. 623-633. ISSN 0190-9622

Proceedings Paper

Cork, M.J. orcid.org/0000-0003-4428-2428, Eichenfield, L.F., Blauvelt, A. et al. (9 more authors) (2019) 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. In: Journal of Investigative Dermatology. Society for Investigative Dermatology (SID) 2019, 08-11 May 2019, Hilton Chicago, Chicago, Illinois. Elsevier , S104-S104.